BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27459982)

  • 1. Timing of Adjuvant Chemotherapy and Impact on Survival for Resected Gastric Cancer.
    Greenleaf EK; Kulaylat AN; Hollenbeak CS; Almhanna K; Wong J
    Ann Surg Oncol; 2016 Dec; 23(13):4203-4213. PubMed ID: 27459982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
    Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
    Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery.
    Kaito A; Kinoshita T; Shitara K; Shibasaki H; Nishida T
    Eur J Surg Oncol; 2017 Apr; 43(4):801-807. PubMed ID: 28187877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early initiation of fluorouracil-based adjuvant chemotherapy improves survival in patients with resectable gastric cancer.
    Qu JL; Qu XJ; Li X; Zhang JD; Teng YE; Jin B; Zhao MF; Yu P; Liu J; Li DY; Liu YP
    J BUON; 2015; 20(3):800-7. PubMed ID: 26214633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.
    Liu Y; Zhang KC; Huang XH; Xi HQ; Gao YH; Liang WQ; Wang XX; Chen L
    World J Gastroenterol; 2018 Jan; 24(2):257-265. PubMed ID: 29375211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer?
    Fujitani K; Kurokawa Y; Takeno A; Endoh S; Ohmori T; Fujita J; Yamasaki M; Takiguchi S; Mori M; Doki Y;
    Gastric Cancer; 2018 May; 21(3):446-452. PubMed ID: 28965205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Analysis of Real-Life Data Evaluating the Optimal Time Between Gastrectomy and Adjuvant Chemotherapy in Resected Gastric Cancer.
    Yücel KB; Sütcüoğlu O; Yazıcı O; Özet A; Özdemir N
    J Gastrointest Cancer; 2023 Dec; 54(4):1268-1275. PubMed ID: 36821038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
    Fukuchi M; Ishiguro T; Ogata K; Suzuki O; Kumagai Y; Ishibashi K; Ishida H; Kuwano H; Mochiki E
    Ann Surg Oncol; 2015 Oct; 22(11):3618-24. PubMed ID: 25663597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
    Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does delayed initiation of adjuvant chemotherapy following the curative resection affect the survival outcome of gastric cancer patients: A systematic review and meta-analysis.
    Lu H; Zhao B; Zhang J; Huang R; Wang Z; Xu H; Huang B
    Eur J Surg Oncol; 2020 Jun; 46(6):1103-1110. PubMed ID: 31948838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
    Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
    Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in postoperative recurrence and prognostic risk factors for patients with gastric cancer who underwent curative gastric resection during different time periods.
    Kim DH; Kim SM; Hyun JK; Choi MG; Noh JH; Sohn TS; Bae JM; Kim S
    Ann Surg Oncol; 2013 Jul; 20(7):2317-27. PubMed ID: 23677605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adjuvant therapy after curative resection with D2 lymphadenectomy for gastric cancer: results of a prospective clinical trial].
    Markelis R; Endzinas Z; Kiudelis M; Grizas S; Pundzius J; Saladzinskas Z; Juozaityte E; Inciūra A; Pranys D; Maleckas A
    Medicina (Kaunas); 2009; 45(6):460-8. PubMed ID: 19605966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer : a propensity-matched analysis.
    Quan R; Huang J; Chen H; Liao Y; Lv W; Chen N; Liu J; Zhang H; Xu D
    Oncotarget; 2016 Nov; 7(46):76316-76326. PubMed ID: 27602756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical gastrectomy with hepatoarterial catheter implantation for late-stage gastric cancer.
    Yao GL; Fan YG; Zhai JM; Lu BS; Liu KL
    World J Gastroenterol; 2015 Mar; 21(9):2754-8. PubMed ID: 25759546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy.
    Beom SH; Choi YY; Baek SE; Li SX; Lim JS; Son T; Kim HI; Cheong JH; Hyung WJ; Choi SH; Jung M; Kim HS; Jeung HC; Chung HC; Rha SY; Noh SH
    BMC Cancer; 2018 Nov; 18(1):1116. PubMed ID: 30442107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of positive transection margins with gastric cancer survival and local recurrence.
    Bickenbach KA; Gonen M; Strong V; Brennan MF; Coit DG
    Ann Surg Oncol; 2013 Aug; 20(8):2663-8. PubMed ID: 23536054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of adjuvant chemotherapy in colorectal cancer.
    Dos Santos LV; Faria TM; Lima AB; Abdalla KC; de Moraes ED; Cruz MR; Lima JP
    Colorectal Dis; 2016 Sep; 18(9):871-6. PubMed ID: 26900665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative adjuvant treatment for gastric cancer improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center.
    Norero E; Bustos M; Herrera ME; Cerda J; González P; Ceroni M; Martínez C; Briceño E; Rojas H; Cártes R; Lopez V; Hidalgo V; Báez S; Caracci M; Viñuela E; Díaz A
    Eur J Surg Oncol; 2016 Jan; 42(1):94-102. PubMed ID: 26577767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer.
    Kanda M; Kobayashi D; Tanaka C; Iwata N; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Nomoto S; Murotani K; Fujiwara M; Kodera Y
    Gastric Cancer; 2016 Jan; 19(1):255-63. PubMed ID: 25563579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.